Clinical trials: Recipients of Allogeneic Stem Cell Transplantation
Cytomegalovirus Infections
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
Patients have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- VICTA (NCT00078533)
- Testing
- CMV CTL infusion
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
This phase I trial studies the side effects of human lysozyme goat milk in preventing graft versus host disease in patients with blood cancer undergoing a donor stem cell transplant.
- Trial name
- NCT04177004
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Tick Borne Encephalitis
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
Patients undergoing allogeneic blood and marrow transplantation (HSCT) experience a prolonged period of dysfunctional immunity. Systematic reimmunization is necessary at appropriate time intervals following transplantation to…
- Trial name
- NCT01991067
- Testing
- TBE virus vaccine
- Where
- Austria
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Hematopoietic and Lymphoid Cell Neoplasm
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant
This pilot trial studies the side effects and how well CBM588 works in improving clinical outcomes in patients who have undergone donor hematopoietic stem cell transplant.
- Trial name
- NCT03922035
- Testing
- Best Practice, Clostridium butyricum CBM 588 Probiotic Strain
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person).
- Conditions
- For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02200380
- Testing
- CDX-301, CDX-301 and plerixafor
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Graft vs Host Disease, Oral Manifestations
Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease
The purpose of this study is to perform a randomized, double-blind, clinical trial comparing the topical treatment with clobetasol or dexamethasone for symptomatic oral lesions of chronic graft-versus-host disease.
- Trial name
- NCT01699412
- Testing
- Clobetasol, Dexamethasone
- Where
- 2 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01588015
- Testing
- tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection
Dried Blood Spot Testing of CMV Detection in HCT Recipients
This is a randomized clinical trial to assess whether a subject centered, self-collection of Dried blood spots (DBS) samples will improve compliance with the clinical recommendation of weekly Cytomegalovirus (CMV) testing of…
- Trial name
- NCT03910478
- Testing
- DBS Self-Collection Kit, Standard Control Strategy
- Where
- 4 sites in United States
- Volunteers
- 622 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Obstructive Airway Disease
Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT
The usual treatment for obstructive airway disease (OAD) after allogeneic hematopoietic stem cell transplantation (AHSCT) , which is related to graft versus host disease (GVHD), consists of intensification of systemic…
- Trial name
- Alloforb (NCT00624754)
- Testing
- Formoterol/Budesonide, lactose
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematopietic Stem Cell Transplantation, Blood Virome
DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients
The Geneva Blood Virome Project is a longitudinal observational study. The main objective is to describe the kinetics of the plasmatic viral load of a selection of at least 21 DNA and RNA viruses of the blood virome in allogeneic…
- Conditions
- Hematopietic Stem Cell Transplantation, Blood Virome, RNA Virus Infections, DNA Virus Infections
- Trial name
- GeBVir (NCT03642977)
- Testing
- Real time PCR and RT-PCR for DNA and RNA viral species
- Where
- Switzerland
- Volunteers
- 112 people
- Sponsor
- University Hospital, Geneva
Prevention of CMV Infection or Disease
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT02137772
- Testing
- Letermovir
- Volunteers
- 570 people
- Sponsor
- Merck Sharp & Dohme LLC
Ocular Graft-versus-host Disease
Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT
Chronic GVHD (cGVHD) is a predominant cause of mortality and disability not related to relapse; it occurs in 30 to 70% of patients.
- Trial name
- NCT06348602
- Testing
- Cyclosporine ophthalmic solution 0.1%, Tacrolimus ophthalmic ointment 0.03%
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Vaccine Response Impaired, Respiratory Syncytial Virus Infections
RSV Vaccine in Transplant Recipients
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied.
- Conditions
- Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression
- Trial name
- RSVax (NCT06593210)
- Testing
- Adjuvant, non-live RSV vaccine
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae.
- Trial name
- NCT00980655
- Testing
- 13vPnC, 23vPS
- Where
- 47 sites in United States, Belgium and 8 more
- Volunteers
- 251 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Allogeneic Hematopoietic Cell Transplantation
A Study of FMT in Patients With AML Allo HSCT in Recipients
This is a randomized, double-blind, placebo-controlled clinical trial of Fecal Microbiota Transplant (FMT) in 2 independent cohorts (60 acute myeloid leukemia patients undergoing intensive chemotherapy and 60 Allo-HCT patients).
- Trial name
- NCT03678493
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Oral Mucositis
Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients
Patients receiving high-dose chemotherapy/conditioning prior to stem cell transplantation (SCT) are at high risk for developing painful lesions in the oral cavity, known as oral mucositis (OM).
- Trial name
- NCT03490396
- Testing
- Gelclair, First® Mouthwash BLM
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Midatech Pharma US Inc.
Stem Cell Transplantation
Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
Introduction. Chronic graft-versus-host-disease (GVHD) is the main late noninfectious complication after allogeneic hematopoietic stem cell transplantation (HSCT) that can affect several organs.
- Trial name
- ALLOVIRO (NCT03684083)
- Testing
- bronchial biopsies
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
The purpose of this study is to 1) evaluate the safety and tolerability, and immunogenicity of blinded V114 and Prevnar 13™ within each vaccination group, and 2) evaluate the safety and tolerability, and immunogenicity of…
- Trial name
- NCT03565900
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Infections, Cytomegalovirus Disease
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus [CMV] infection) based on the recovery of the patient's own immune…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
- Trial name
- NCT07569653
- Testing
- CMV-Specific T-cell Guided Letermovir Discontinuation, Standard Letermovir Prophylaxis
- Where
- 12 sites in China
- Volunteers
- 120 people
- Sponsor
- WeiShi
Physiological Stress
Exercise and Stress Management Post Autologous and Allogeneic Transplant (BMT CTN 0902)
This is a Phase III, randomized, unblinded, multicenter, prospective comparative study. The purpose of this study is to test whether exercise or stress management training delivered to autologous and allogeneic hematopoietic cell…
- Trial name
- NCT01278927
- Testing
- Exercise, Stress Management, Exercise and Stress Management
- Where
- 19 sites in United States
- Volunteers
- 711 people
- Sponsor
- Medical College of Wisconsin